Abstract
HSF1 (Heat Shock transcription Factor 1) is the main transcription factor activated in response to proteotoxic stress. Once activated, it induces an expression of heat shock proteins (HSPs) which enables cells to survive in suboptimal conditions. HSF1 could be also activated by altered kinase signaling characteristic for cancer cells, which is a probable reason for its high activity found in a broad range of tumors. There is rapidly growing evidence that HSF1 supports tumor initiation and growth, as well as metastasis and angiogenesis. It also modulates the sensitivity of cancer cells to therapy. Functions of HSF1 in cancer are connected with HSPs’ activity, which generally protects cells from apoptosis, but also are independent of its classical targets. HSF1-dependent regulation of non-HSPs genes plays a role in cell cycle progression, glucose metabolism, autophagy and drug efflux. HSF1 affects the key cell-survival and regulatory pathways, including p53, RAS/MAPK, cAMP/PKA, mTOR and insulin signaling. Although the exact mechanism of HSF1 action is still somewhat obscure, HSF1 is becoming an attractive target in anticancer therapies, whose inhibition could enhance the effects of other treatments.
Keywords: Cancer, drug resistance, genomic instability, HSF1 inhibitors, HSPs, metastasis, p53 signaling.
Current Cancer Drug Targets
Title:Pleiotropic Role of HSF1 in Neoplastic Transformation
Volume: 14 Issue: 2
Author(s): Natalia Vydra, Agnieszka Toma and Wieslawa Widlak
Affiliation:
Keywords: Cancer, drug resistance, genomic instability, HSF1 inhibitors, HSPs, metastasis, p53 signaling.
Abstract: HSF1 (Heat Shock transcription Factor 1) is the main transcription factor activated in response to proteotoxic stress. Once activated, it induces an expression of heat shock proteins (HSPs) which enables cells to survive in suboptimal conditions. HSF1 could be also activated by altered kinase signaling characteristic for cancer cells, which is a probable reason for its high activity found in a broad range of tumors. There is rapidly growing evidence that HSF1 supports tumor initiation and growth, as well as metastasis and angiogenesis. It also modulates the sensitivity of cancer cells to therapy. Functions of HSF1 in cancer are connected with HSPs’ activity, which generally protects cells from apoptosis, but also are independent of its classical targets. HSF1-dependent regulation of non-HSPs genes plays a role in cell cycle progression, glucose metabolism, autophagy and drug efflux. HSF1 affects the key cell-survival and regulatory pathways, including p53, RAS/MAPK, cAMP/PKA, mTOR and insulin signaling. Although the exact mechanism of HSF1 action is still somewhat obscure, HSF1 is becoming an attractive target in anticancer therapies, whose inhibition could enhance the effects of other treatments.
Export Options
About this article
Cite this article as:
Vydra Natalia, Toma Agnieszka and Widlak Wieslawa, Pleiotropic Role of HSF1 in Neoplastic Transformation, Current Cancer Drug Targets 2014; 14 (2) . https://dx.doi.org/10.2174/1568009614666140122155942
DOI https://dx.doi.org/10.2174/1568009614666140122155942 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry Relevance of Breast Cancer Resistance Protein to Brain Distribution and Central Acting Drugs: A Pharmacokinetic Perspective
Current Drug Metabolism Modulation of Poly(A)-specific Ribonuclease (PARN): Current Knowledge and Perspectives
Current Medicinal Chemistry Molecular Cytogenetics and Cytogenomics of Brain Diseases
Current Genomics Metastatic Cancer Stem Cells: New Molecular Targets for Cancer Therapy
Current Pharmaceutical Biotechnology Stem Cells as In Vitro Models of Disease
Current Stem Cell Research & Therapy Ferroptosis: A Novel Mechanism of Artemisinin and its Derivatives in Cancer Therapy
Current Medicinal Chemistry Analytical Approaches for Assaying Metallodrugs in Biological Samples: Recent Methodological Developments and Future Trends
Current Drug Metabolism Genetic Chemoprotection with Mutant O6-Alkylguanine-DNA-Alkyltransferases
Current Gene Therapy Development and Clinical Application of Tumor-derived Exosomes in Patients with Cancer
Current Stem Cell Research & Therapy The Other Side of Opioid Receptor Signalling: Regulation by Protein-Protein Interaction
Current Drug Targets 64Cu Labeled AmBaSar-RGD2 for micro-PET Imaging of Integrin αvβ3 Expression
Current Radiopharmaceuticals Eph/Ephrin Signalling and Function in Oncogenesis: Lessons from Embryonic Development
Current Cancer Drug Targets Crossed Cerebellar Diaschisis in Alzheimer’s Disease
Current Alzheimer Research Exosomes Harnessed as Nanocarriers for Cancer Therapy - Current Status and Potential for Future Clinical Applications
Current Molecular Medicine Active Targeting Towards and Inside the Brain based on Nanoparticles: A Review
Current Pharmaceutical Biotechnology Natural Anti-inflammatory Compounds as Drug Candidates in Alzheimer’s Disease
Current Medicinal Chemistry Molecular Fundamentals and Rationale for Immunotherapy in Metastatic Melanoma Treatment
Clinical Cancer Drugs miRNAs as Modulators of Cholesterol in Breast Cancer Stem Cells: An Approach to Overcome Drug Resistance in Cancer
Current Drug Targets Neovascular Age-related Macular Degeneration: Past, Present, and Future
Current Angiogenesis (Discontinued)